ADNI3 begin in 2016. Between 1070-2000 participants will be enrolled: approximately 700-800 rollover participants from ADNI2 and 370-1200 newly enrolled subjects.  Clinical, cognitive, imaging, biomarker and genetic characteristics will be assessed across three cohorts: Cognitively normal, MCI and mild AD dementia.

ADNI3: WHAT’S NEW

In addition to all the biomarkers used in ADNI 2, ADNI 3 has the following changes and additions:

1. ADNI 3 includes longitudinal tau PET scans with AV 1451 provided by AVID. The study also includes the development of tau PET as a surrogate outcome measure for AD clinical trials.

2. For new ADNI 3 subjects, we will be using Florbetaben provided by Piramal for amyloid PET.

3. CSF amyloid and tau will be measured using a new immunoassay platform provided by Roche to determine how tau tangles are related to amyloid levels and to cognition.

4. MRI techniques from the Human Connectome Project will be used to map the effects of AD on brain connectivity. Protocols will be updated including 3D ASL perfusion imaging and Connectome sequences for appropriate scanners.

5. Use of high-powered MRI to detect very early structural brain changes in AD.

6. For the clinical battery, the Financial Capacity Instrument has been added and subjects will take Cogstate computerized testing in-clinic and at home and subjects will be invited to join the Brain Health Registry for at-home assessment. The Brain Health Registry also supports recruitment activities.

7. Use of Systems Biology approaches to understand AD genetics and its relationship to AD biology.

8. Development of models to select patients for AD clinical trials using Precision medicine

The figure is from https://ida.loni.usc.edu/home/projectPage.jsp?project=ADNI&page=HOME&subPage=OVERVIEW_PR#